US Latino patients with atherosclerotic cardiovascular disease (ASCVD) are missing out on Lp(a) testing despite the fact that cardiovascular disease is the leading cause of death in this group. A retrospective cohort study compared Lp(a) testing in Latino and non-Latino patients using medical records from 87 US health systems and 1:1 nearest-neighbour greedy propensity score matching to balance baseline characteristics.
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
